YOLFTbeta
04

Hyundai Bioscience Co. Ltd

048410 · KQ · Healthcare / Biotechnology

6,170.00KRW+500.00 (+8.82%)

Price History

Full chart

Market Stats

Previous Close5,670.00
Open5,720.00
Day Range5,720.00 – 6,850.00
52-Week Range4,565.00 – 21,500.00
Volume3.17M
Market Cap685.17B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.87
50-Day Avg6,700.60
200-Day Avg9,647.23

About

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOJong-Won Choi
  • Employees69
  • Headquarters150, Bugahyeon-ro, Seoul, South Korea, 03759, Korea
  • Websitehttps://www.hyundaibioscience.com

Leadership

  • Jong-Won ChoiJoint Chief Executive Officer · b. 1967
  • Ho-Suk ChonJoint Chief Executive Officer · b. 1958
  • Yeong-Jin KimPresident · b. 1970
  • Seok-Yong ChoiChief Operating Officer and Senior Managing Director · b. 1962

Financials

Income Statement

Currency: KRW2002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue344.71B463.87B567.06B414.10B228.83B117.17B118.87B93.93B86.34B47.65B37.08B25.75B28.91B40.67B36.10B31.97B31.24B30.09B12.51B9.24B7.85B9.48B15.05B3.52B
Growth (%)-+34.57%+22.25%-26.97%-44.74%-48.79%+1.45%-20.99%-8.08%-44.81%-22.19%-30.56%+12.29%+40.68%-11.24%-11.44%-2.30%-3.68%-58.41%-26.14%-15.04%+20.76%+58.73%-76.63%
Cost of Revenue305.32B404.76B506.29B372.84B217.35B106.72B109.62B80.51B69.19B37.59B26.55B18.57B19.69B28.49B24.10B17.14B16.89B15.96B5.95B5.72B5.17B4.44B3.18B3.27B
Gross Profit------------8.36B12.19B12.00B14.83B14.35B14.12B6.56B3.52B2.68B5.04B11.87B243.63M
Gross Margin------------28.90%29.96%33.24%46.38%45.93%46.94%52.45%38.10%34.17%53.17%78.84%6.93%
Operating Expense------------7.71B10.83B18.96B13.36B12.20B11.57B13.93B20.81B20.67B19.60B11.07B18.40B
Operating Income-4.25B----------646.64M1.36B-6.96B1.46B2.15B2.56B-7.37B-17.29B-17.99B-14.55B790.97M-18.16B
Operating Margin-0.92%----------2.24%3.33%-19.29%4.58%6.88%8.49%-58.90%-187.06%-229.11%-153.50%5.26%-516.32%
EBITDA---------------------14.38B-12.75B-3.94B-18.36B
EBITDA Margin---------------------183.17%-134.46%-26.18%-522.09%
Net Income-6.78B---1.91B5.26B------3.11B711.29M-8.07B1.22B2.62B767.22M-8.61B-20.05B-15.81B-14.50B-6.93B-22.13B
Net Income Margin-1.46%---1.63%4.42%------10.75%1.75%-22.35%3.81%8.38%2.55%-68.79%-216.97%-201.33%-152.92%-46.04%-629.12%
R&D--------2.07B1.73B1.71B1.79B414.00M1.15B2.11B2.05B1.70B1.29B1.97B4.76B16.46B6.40B3.06B7.60B
R&D as % of Total Revenue--------2.40%3.62%4.60%6.94%1.43%2.82%5.86%6.41%5.45%4.29%15.73%51.53%209.59%67.51%20.30%215.93%
Interest Expense0000000000000000001.13B3.00B448.65M314.57M2.31B2.43B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%9.03%32.49%5.71%3.32%15.37%69.23%

Balance Sheet

Currency: KRW2002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets200.60B242.55B224.80B230.83B105.52B103.16B87.53B61.19B48.45B30.47B32.06B30.84B32.81B43.41B53.38B49.50B54.01B63.24B92.31B80.53B67.33B52.79B67.70B130.74B
Total Liabilities136.52B174.21B163.86B191.51B146.06B44.92B37.17B21.89B16.37B16.30B13.16B9.04B10.32B18.81B35.17B18.61B13.52B16.25B41.09B18.96B9.09B7.52B28.27B20.01B
Total Equity64.08B68.34B60.94B39.33B-58.24B50.36B39.30B32.08B14.17B18.90B21.80B22.49B24.60B18.21B30.89B40.48B46.99B51.22B61.57B58.24B45.27B39.44B110.73B
Cash18.14B36.68B30.02B24.43B12.04B16.98B25.71B4.12B5.13B4.17B2.08B1.96B2.17B11.91B9.74B4.85B3.16B5.56B19.21B9.19B2.73B1.81B3.66B22.34B
Total Debt-------------13.37B15.34B-6.04B5.49B35.93B-----
Net Debt------------------17.13B5.77B3.28B3.59B22.18B-

Cash Flow

Currency: KRW2003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-----10.37B--3.97B--1.22B87.36M-4.34B-3.70B5.01B9.18B7.50B-538.48M-16.54B-6.01B2.26B-17.05B
Investing Cash Flow-----8.21B-3.16B----2.71B212.89M-9.98B654.91M-4.63B-14.70B-26.83B-12.36B8.52B5.18B-19.74B-
Financing Cash Flow28.50B18.19B31.91B5.69B42.15B--2.17B-11.87B8.94B1.55B9.44B12.12B-1.75B-2.10B7.88B32.95B2.99B1.67B-57.97M19.19B-
Capital Expenditure4.19B11.18B3.47B2.88B458.62M3.92B2.79B62.91M267.78M3.73B308.17M840.18M647.57M6.98B1.47B7.07B3.07B25.20B3.76B1.54B587.54M2.17B20.19B
Free Cash Flow-----------------4.06B-17.70B-4.30B-18.09B-6.60B87.48M-37.24B
Dividends Paid1.88B1.86B---------------------
FCF to OCF-----------------44.24%-235.97%798.63%109.33%109.78%3.88%218.44%

Earnings

Report DateMar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Mar 17, 2021May 17, 2021Aug 17, 2021Nov 15, 2021Feb 24, 2022May 16, 2022Aug 16, 2022Nov 14, 2022Feb 27, 2023May 15, 2023Aug 11, 2023Nov 14, 2023Mar 14, 2024May 16, 2024Aug 14, 2024Nov 12, 2024Dec 31, 2024May 15, 2025Aug 12, 2025Nov 12, 2025Mar 16, 2026May 13, 2026Jun 30, 2026
EPS Estimate--------------------------------------------------------------
EPS Actual-557.90-1748.15-1208.57-385.90-41.07-44.14-66.79-0.01-33.08-55.40-22.16-66.29-12.83-12.312.06-28.672.574.5214.64-10.692.27-4.18-32.98-90.47-17.281.029.0523.67-4.801.7110.4929.187.714.2411.16-12.34-15.45-2.37-4.22-192.81-55.72-53.19-70.69-349.56-55.11-149.1584.72-288.33-52.82-58.73-49.72-203.1329.7757.94-128.77-57.46-139.77-44.28-72.86-49.35-55.26-120.23
Surprise--------------------------------------------------------------
Timing-------------------------------------------Pre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-Pre-marketPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap685.17B
Enterprise Value641.27B
Trailing P/E0.00
Forward P/E0.00
Price / Sales206.62
Price / Book6.40
Revenue (TTM)3.32B
Gross Profit (TTM)-250.63M
EBITDA-17.87B
Profit Margin0.00%
Operating Margin-1064.26%
Return on Equity-24.29%
Return on Assets-9.60%
Shares Outstanding96.50M
Shares Float85.28M
Beta0.87
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20031×
3284.68Dec 29, 2003
20021×
3284.68Dec 27, 2002

Stock Splits

  • Jul 24, 20252:1
  • Dec 17, 2024698:657
  • Jul 12, 2013605:563
  • Jan 9, 20121:10
  • Mar 21, 20071:30
  • Apr 20, 20042:1